ENDRA Life Sciences (NASDAQ:NDRA) Shares Up 6.5% – Here’s What Happened

ENDRA Life Sciences Inc. (NASDAQ:NDRA)’s stock price shot up 6.5% on Friday . The company traded as high as $6.37 and last traded at $6.05. Approximately 20,582 shares traded hands during mid-day trading, a decline of 50% from the average session volume of 41,006 shares. The stock had previously closed at $5.68.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on NDRA. Weiss Ratings cut shares of ENDRA Life Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, August 13th. Ascendiant Capital Markets reduced their target price on shares of ENDRA Life Sciences from $27.00 to $25.00 and set a “buy” rating for the company in a research note on Monday, June 1st. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, ENDRA Life Sciences currently has a consensus rating of “Hold” and an average price target of $25.00.

ENDRA Life Sciences Trading Up 6.5%

The stock has a fifty day simple moving average of $4.93 and a two-hundred day simple moving average of $4.72. The company has a market cap of $9.07 million, a PE ratio of -0.95 and a beta of -0.05.

ENDRA Life Sciences (NASDAQ:NDRA) last issued its earnings results on Friday, August 14th. The company reported ($0.63) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.84) by $0.21. As a group, equities research analysts anticipate that ENDRA Life Sciences Inc. will post -4.11 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in ENDRA Life Sciences stock. Altium Capital Management LLC bought a new stake in ENDRA Life Sciences Inc. (NASDAQ:NDRA) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 51,900 shares of the company’s stock, valued at approximately $235,000. ENDRA Life Sciences accounts for approximately 0.9% of Altium Capital Management LLC’s portfolio, making the stock its 17th biggest holding. Altium Capital Management LLC owned 6.92% of ENDRA Life Sciences as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 1.19% of the company’s stock.

ENDRA Life Sciences Company Profile

ENDRA Life Sciences, Inc (NASDAQ: NDRA) is a medical technology company headquartered in Ann Arbor, Michigan, that focuses on the development and commercialization of Thermoacoustic Enhanced Ultrasound (TAEUS™) imaging. The company’s proprietary TAEUS platform combines conventional ultrasound with thermoacoustic signals to provide non-invasive, real-time temperature monitoring of soft tissue. This technology is designed to improve the safety, efficacy and outcomes of thermal ablation procedures and other heat-based therapies.

ENDRA’s core product line centers on a compact, easy-to-integrate device that augments existing ultrasound systems.